Enrolling

This study will assess the safety and neutralizing activity of AZD3152 in adults and adolescents 12 years of age or older (weighing at least 40 kg) with conditions causing immune impairment, who are less likely to mount an adequate protective immune response after vaccination and thus are at high risk of developing severe COVID-19. Read more at:

• https://www.astrazeneca-us.com/media/statements/2022/first-participant-dosed-in-supernova-phase-I-III-trial-evaluating-azd5156-a-next-generation-long-acting-antibody-combination-for-prevention-of-covid-19.html
• https://www.cdc.gov/mmwr/volumes/72/wr/mm7205e3.htm?s_cid=mm7205e3_w
• https://clinicaltrials.gov/ct2/show/NCT05648110

Treatment Dosed Every 6 Months in Virologically Suppressed Adults With HIV-1 Infection The study will evaluate the efficacy of switching to a regimen of single antiretroviral lenacapavir (LEN) in combination with two biologics Teropavimab and Zinlirvimab versus continuing on baseline oral ART. Read more:

• https://www.nejm.org/doi/full/10.1056/NEJMoa2115542
• https://www.gilead.com/news-and-press/press-room/press-releases/2023/2/gilead-presents-positive-proof-of-concept-data-for-investigational-combination-regimen-of-lenacapavir-with-broadly-neutralizing-antibodies-as-a-potent
• https://www.clinicaltrials.gov/study/NCT05729568
• https://www.clinicaltrialsarena.com/news/gilead-sciences-hiv-therapy-trial/

The purpose of this study is to demonstrate the efficacy of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared to placebo in the prevention of the first invasive extraintestinal pathogenic Escherichia coli disease (IED) event caused by ExPEC9V O-serotypes. Read more: https://clinicaltrials.gov/ct2/show/NCT04899336 https://en-us.embracevaccinestudy.com/ https://www.jnj.com/innovation/meet-janssen-researcher-working-on-human-e-coli-vaccine